vTv Therapeutics Grants Stock Options
Analysis based on 7 articles · First reported Jun 02, 2026 · Last updated Jul 02, 2026
The granting of stock options by vTv Therapeutics to its employees is a routine corporate action aimed at employee retention and motivation. While these specific grants are relatively small in number, they reflect the company's ongoing efforts to incentivize its workforce, which can be seen as a positive signal for its long-term stability and development, particularly concerning its lead drug candidate, Cadisegliatin. The market impact is likely minimal as these are standard inducement grants.
vTv Therapeutics Inc., a late-stage biopharmaceutical company, announced multiple grants of stock options to non-executive employees as material inducements to employment. On July 2, 2026, the company granted 12,500 stock options to two employees with a weighted average exercise price of $34.15 per share. Earlier, on June 2, 2026, vTv Therapeutics granted 2,500 stock options to a non-executive employee at an exercise price of $34.30 per share. These options vest over a four-year period and are subject to the terms of the 2026 Inducement Plan and stock option agreements. The grants are in accordance with Nasdaq-100 Listing Rule 5635(c)(4) and aim to attract and retain talent crucial for the development of its clinical pipeline, including Cadisegliatin, an oral adjunctive therapy for type 1 diabetes.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard